Skip to main
KZR
KZR logo

KZR Stock Forecast & Price Target

KZR Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Kezar Life Sciences Inc. has seen a positive shift in investor confidence following the lifting of the partial clinical hold in the autoimmune hepatitis (AIH) indication for its lead candidate, Zetomipzomib (KZR-616). The potential full removal of the clinical hold in lupus nephritis (LN) is expected to significantly boost investor sentiment and could facilitate clinical uptake if the product is approved. Overall, these developments may enhance the commercial prospects for Zetomipzomib, thereby positively influencing the company's future financial outlook.

Bears say

Kezar Life Sciences Inc. has demonstrated challenges in advancing its clinical-stage pipeline, particularly due to delays in clinical trials and the lengthy regulatory approval process typical of biotechnology firms. Additionally, the company faces significant cash burn rates which raise concerns about its ability to fund operations and development without securing further capital. Lastly, the competitive landscape in the biotechnology sector, coupled with the ongoing uncertainty surrounding the success of their product candidates like Zetomipzomib and KZR-261, contributes to a heightened risk for investors.

KZR has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kezar Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kezar Life Sciences Inc (KZR) Forecast

Analysts have given KZR a Hold based on their latest research and market trends.

According to 2 analysts, KZR has a Hold consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kezar Life Sciences Inc (KZR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.